J-S Hulot
Overview
Explore the profile of J-S Hulot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
886
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scott S, Collet J, Baber U, Yang Y, Peter I, Linderman M, et al.
Clin Pharmacol Ther
. 2016 May;
100(3):287-94.
PMID: 27213804
Interindividual variability in platelet aggregation is common among patients treated with clopidogrel and both high on-treatment platelet reactivity (HTPR) and low on-treatment platelet reactivity (LTPR) increase risks for adverse clinical...
2.
Jolly M, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al.
Lupus
. 2016 Feb;
25(7):735-40.
PMID: 26876692
Objectives: Benefits of hydroxychloroquine (HCQ) use on physician reported outcomes are well documented in systemic lupus erythematosus (SLE). We assess for the first time the association and predictive value of...
3.
Corvol J, Devos D, Hulot J, Lacomblez L
Rev Neurol (Paris)
. 2015 May;
171(6-7):482-97.
PMID: 26008819
Introduction: Pharmacogenetics aims to identify the underlying genetic factors participating in the variability of drug response. Indeed, genetic variability at the DNA or RNA levels can directly or indirectly modify...
4.
Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D, et al.
Clin Pharmacol Ther
. 2013 May;
94(3):317-23.
PMID: 23698643
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles...
5.
Gottesman O, Scott S, Ellis S, Overby C, Ludtke A, Hulot J, et al.
Clin Pharmacol Ther
. 2013 Apr;
94(2):214-7.
PMID: 23588317
No abstract available.
6.
Simon N, Marsot A, Villard E, Choquet S, Khe H, Zahr N, et al.
Pharmacogenomics J
. 2012 Oct;
13(6):507-13.
PMID: 23069858
Human multidrug resistance-related protein 2 (MRP2, encoded by ABCC2) is involved in the transport of anionic drugs such as methotrexate (MTX). We prospectively investigated the influence of four common ABCC2...
7.
Hulot J, Senyei G, Hajjar R
Gene Ther
. 2012 Jun;
19(6):596-9.
PMID: 22673498
Although progress in conventional treatments is making steady and incremental gains to reduce mortality associated with heart failure (HF), there remains a need to explore potentially new therapeutic approaches. HF...
8.
Martis S, Peter I, Hulot J, Kornreich R, Desnick R, Scott S
Pharmacogenomics J
. 2012 Apr;
13(4):369-77.
PMID: 22491019
To determine CYP2C19 and CYP2C8 allele frequencies, 28 coding and/or functional variants were genotyped in 1250 African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish (AJ) individuals. The combined CYP2C19 variant allele...
9.
Scott S, Sangkuhl K, Gardner E, Stein C, Hulot J, Johnson J, et al.
Clin Pharmacol Ther
. 2011 Jul;
90(2):328-32.
PMID: 21716271
No abstract available.
10.
Hulot J, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S, et al.
J Thromb Haemost
. 2009 Dec;
8(3):610-3.
PMID: 20040040
No abstract available.